Table 2.
Between-treatment percentage change in bone mineral density in postmenopausal women with osteopenia receiving one of two zoledronic acid regimens or placebo for 24 months [McClung et al. 2009].
| Efficacy variable | ZOL 2×5 mg* n = 198 | ZOL 1×5 mg$ n = 181 | Placebo n = 202 |
|---|---|---|---|
| Lumbar spine BMD | |||
| LSM (SE) | 5.18 (0.272) | 4.42 (0.279) | −1.32 (0.268) |
| Total hip BMD | |||
| LSM (SE) | 2.91 (0.207) | 2.28 (0.216) | −1.45 (0.202) |
| Femoral neck BMD | |||
| LSM (SE) | 2.20 (0.294) | 1.64 (0.308) | −1.35 (0.288) |
| Trochanter BMD | |||
| LSM (SE) | 4.83 (0.278) | 4.16 (0.290) | −1.15 (0.272) |
| Distal radius BMD | |||
| LSM (SE) | −0.07 (0.255) | −0.18 (0.266) | −2.39 (0.248) |
*
ZOL 2×5 mg, zoledronic acid received at randomization and at month 12;
$
ZOL 1×5 mg, zoledronic acid received at randomization and placebo received at Month 12.
n, number of subjects; BMD, bone mineral density; LSM, least squares mean; SE, standard error.